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Patients or Patents?
Intellectual property rights and access to medicine in Northern India
Marginean, Valentina
Ohio Wesleyan University
School for International Training (SIT), New Delhi, India: Public Health, Policy Advocacy, and Community Engagement 
Introduction
The Indian public healthcare system’s health inequities,
perpetuated by institutionalized stratification, racism and
elitism, impedes the average Indian’s access to
healthcare. To compensate for these inequities, India
utilizes its generic drug industry to supply medicine at free
or reduced costs through central and state government
schemes. However, certain medicines still cost more than
the average monthly salary can afford1. The role of this
study is to examine the influence of intellectual property
rights in the Indian pharmaceutical market. This study
provides qualitative data that supports a direct
relationship between intellectual property rights and
price-control mechanisms, which influence
pharmaceutical companies’ profit margin and therefore
inhibit access to medicine by making drugs more costly.
Background
Methods
The data was collected through secondary literature
review, interviews, and observation through
shadowing pertinent stakeholders such as
legislatures, nongovernment organizations (NGOs)
and pharmaceutical representatives:
 Questionnaire and personal interviews.
 Group discussions and intertwining data analysis.
 Relate data back to current domestic legislation
and trade agreements.
 Data collection of various drug costs across various
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In response to the 1995 Trade-Related Aspects of
Intellectual Property Rights (TRIPS) Agreement, India
was one of the first countries to apply public health
safeguards2.
Patent Law
Price-Control Mechanisms
Figure 2. Compulsory licensing and anti-evergreening clauses in
India’s Patent Act of 2005 have been a significant method of
facilitating access to medicine for millions of Indians and foreigners.
Figure 3. Procurement/tender price comparison of selected few
generic medicines procured by the Rajasthan Medical Services
Corporation (RMSC) with their corresponding branded drugs in
2014. At the time of the data, profit margin control occurred directly
through the Drug Price Control Order (DPCO) which
compartmentalized drugs and specified a maximum allowable
post-manufacturing expense for each category3,1. This figure
demonstrates that private dispensaries are not abiding by DPCO
policy.
Figure 1. It has been well-studied in human rights discourse and access
to medicine issues that intellectual property rights post-1995 have
played a role in the global pharmaceutical market. This is because
loose intellectual property rights have the ability to stifle growth in the
generic market.
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Given India’s role as a rising economic powerhouse,
intellectual property rights could become a
determinant in India’s status as a developing versus
developed country. There are several domestic and
international barriers that affect health delivery of
generic medicines, such as economic pressures and
intellectual property rights. Some issues this field
study addresses are price control mechanisms and
research and development. Other issues include
India’s high poverty rate and lack of everyday
access to medicines. The central government has
several schemes in place for free delivery of
essential medicines. Despite these schemes, price-
control mechanisms remain a challenge to
accessing medicine in Northern India.
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